Ipsen: Karen Witts Leaves Board, Pascal Touchon Takes Over as Interim Audit Committee Chair
Ipsen announced the resignation of Karen Witts from her role as a board member, effective after the Annual General Meeting on May 13, 2026. Having served as the Chair of the Audit Committee since 2022, she is stepping down to focus on her other professional responsibilities.
Audit Committee Succession Entrusted to Pascal Touchon
Karen Witts, who has been a board member at Ipsen since January 20, 2022, submitted her resignation to focus on her executive duties. Serving as the Chair of the Audit Committee from 2022 to 2026 and as a member of the Compensation Committee, she has contributed significantly to the Board's work over her four-year term.
Marc de Garidel, Chairman of the Board, thanked Karen Witts for "her dedication, meticulousness, and commitment during her tenure on the Board and for her significant contributions, particularly in her role as Chair of the Audit Committee."
Succession Process Underway
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The Nominations Committee has initiated a succession process to replace Karen Witts. Pending its completion, Pascal Touchon, an independent board member and member of the Audit Committee, has been appointed as the interim Chair of the Audit Committee and, also on an interim basis, as a member of the Compensation Committee. This decision was made at the Board of Directors meeting held on May 13, 2026, following the Annual General Meeting.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 2 190 millions d'euros
Quarterly revenue: 2 190 millions d'euros
Revenue growth: 20,4 %
EBITDA: 733,9 millions d'euros
EBITDA margin: 40,7 %
Net income: 403,1 millions d'euros
Free cash flow: 651,7 millions d'euros
-1 005 millions d'euros
Guidance from the release
Cette dynamique nous permet de relever nos objectifs financiers pour 2026
Risks mentioned
Arrivée potentielle de génériques du lanréotide, concurrençant les ventes de Somatuline
Effet défavorable des devises d'environ 1 % anticipé sur l'exercice 2026
Impact dilutif des acquisitions de Memo Therapeutics AG et de Kartos Therapeutics sur la marge
Opportunities identified
Plusieurs lancements attendus à court terme d'actifs à potentiel de blockbuster dans les trois aires thérapeutiques
Résultats positifs de Phase III de Dysport dans la migraine épisodique et chronique
Résultats positifs de Phase IIIb ELSPIRE d'Iqirvo dans la cholangite biliaire primitive
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
